Antioxidant and Hepatoprotective Activity of a New Tablets Formulation from Tamarindus indica L.

Table 4

Effect of Tamarindus indica L. tablets on serum lipid profile in CCl₄ induced hepatotoxicity in Sprague Dawley rats.

Group	TG; (mg/dL)	CHOL; (mg/dL)	HDL-c; (mg/dL)	LDL-c; (mg/dL)	VLDL-c; (mg/dL)
I	48.41 2.26	94.91 3.16	49.59 1.83	35.64 1.75	9.68 0.95
II	120.57 6.90	151.00 3.43	25.98 2.06	100.91 5.43	24.11 1.32
III	56.88 2.94	96.56 2.78	51.24 1.16	33.94 2.02	11.38 1.59
IV	52.32 3.39	92.58 2.99	46.41 1.40	35.71 0.98	10.46 0.98
V	50.83 2.04	90.59 2.71	48.29 1.33	32.13 1.95	10.17 0.91

TG: triglycerides, CHOL: cholesterol, HDL: high-density lipoproteins, LDL: low-density lipoproteins, and VLDL: very low-density lipoproteins (-c, bounded to cholesterol).
I: normal group; II: CCl₄ induced hepatotoxicity group; III: Silymarin treated group; IV and V: Tamarindus indica L. tablets treated groups at doses 100 mg/kg and 200 mg/kg, respectively.
Different letters on columns indicate significant statistical differences in Tukey HSD test.
Data are expressed as mean SD; .